A股異動丨博雅生物漲停 人免疫球蛋白需求或放量
格隆匯2月6日丨博雅生物(300294.SZ)漲停,報36.18元,總市值156.78億元。

日前,上海萊士收到《生產能力應急徵用通知》,南嶽生物製藥公司積極復工。在抗擊冠狀病毒感染的肺炎工作中,各地衞健委以及各大醫院都制定了防治方案,將免疫球蛋白列入。分析稱,目前血製品行業基本處於去庫存末期,短期而言,隨着新型肺炎的不斷進展,人免疫球蛋白的需求量會越來越大。博雅生物主營業務為從事血液製品的研發、生產和銷售,主要產品為人血白蛋白、靜注人免疫球蛋白(靜丙)和纖維蛋白原。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.